HY-139284 Search Results


gw0742  (MedChemExpress)
94
MedChemExpress gw0742
Gw0742, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gw0742/product/MedChemExpress
Average 94 stars, based on 1 article reviews
gw0742 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
polθi art812  (MedChemExpress)
92
MedChemExpress polθi art812
Pol θ i enhanced the sensitivity of DNMT3A deficient leukemia cells to standard drugs. ( A-D ) Sensitivity of FLT3(ITD); Dnmt3a KD 32Dcl3 cells (32D), FLT3(ITD);DNMT3A(R882H) Lin - CD34 + AML primary (AML) cells and Lin - CD34 + normal bone marrow cells (NBMCs) to Polθi (25 μM ART558, 50μM <t>ART812,</t> 4μM RP-6685) +/- ( A ) 2.5 nM quizartinib, ( B ) 60 nM etoposide, ( C ) 0.2 μM cytarabine, and ( D ) 0.25μM azacytidine. Results represent mean number of colonies. ( E, F ) FLT3(ITD); Dnmt3a KD 32Dcl3 cells (32D) were untreated, or treated with 4 μM RP-6685 and/or 60nM etoposide. ( E ) Mean number of DPCs. ( F ) Mean % of DNA in the tail. ( G ) A scheme of in vivo experiments. ( H ) Mean number of GFP + FLT3(ITD); Dnmt3a KD 32Dcl3 cells (FD cells) in PBL of SCID mice untreated (Control) and treated with RP-6685, etoposide (ETO) and the combination (RP-6685+ETO). ( I ) Survival curves and MST of the mice. Error bars represent the SD; p values were calculated using one- way Anova ( A-F, H ); mice survival was evaluated by Kaplan-Meier LogRank test.
Polθi Art812, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/polθi art812/product/MedChemExpress
Average 92 stars, based on 1 article reviews
polθi art812 - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier
m1002  (MedChemExpress)
93
MedChemExpress m1002
Pol θ i enhanced the sensitivity of DNMT3A deficient leukemia cells to standard drugs. ( A-D ) Sensitivity of FLT3(ITD); Dnmt3a KD 32Dcl3 cells (32D), FLT3(ITD);DNMT3A(R882H) Lin - CD34 + AML primary (AML) cells and Lin - CD34 + normal bone marrow cells (NBMCs) to Polθi (25 μM ART558, 50μM <t>ART812,</t> 4μM RP-6685) +/- ( A ) 2.5 nM quizartinib, ( B ) 60 nM etoposide, ( C ) 0.2 μM cytarabine, and ( D ) 0.25μM azacytidine. Results represent mean number of colonies. ( E, F ) FLT3(ITD); Dnmt3a KD 32Dcl3 cells (32D) were untreated, or treated with 4 μM RP-6685 and/or 60nM etoposide. ( E ) Mean number of DPCs. ( F ) Mean % of DNA in the tail. ( G ) A scheme of in vivo experiments. ( H ) Mean number of GFP + FLT3(ITD); Dnmt3a KD 32Dcl3 cells (FD cells) in PBL of SCID mice untreated (Control) and treated with RP-6685, etoposide (ETO) and the combination (RP-6685+ETO). ( I ) Survival curves and MST of the mice. Error bars represent the SD; p values were calculated using one- way Anova ( A-F, H ); mice survival was evaluated by Kaplan-Meier LogRank test.
M1002, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/m1002/product/MedChemExpress
Average 93 stars, based on 1 article reviews
m1002 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
hy13928  (Selleck Chemicals)
93
Selleck Chemicals hy13928
Pol θ i enhanced the sensitivity of DNMT3A deficient leukemia cells to standard drugs. ( A-D ) Sensitivity of FLT3(ITD); Dnmt3a KD 32Dcl3 cells (32D), FLT3(ITD);DNMT3A(R882H) Lin - CD34 + AML primary (AML) cells and Lin - CD34 + normal bone marrow cells (NBMCs) to Polθi (25 μM ART558, 50μM <t>ART812,</t> 4μM RP-6685) +/- ( A ) 2.5 nM quizartinib, ( B ) 60 nM etoposide, ( C ) 0.2 μM cytarabine, and ( D ) 0.25μM azacytidine. Results represent mean number of colonies. ( E, F ) FLT3(ITD); Dnmt3a KD 32Dcl3 cells (32D) were untreated, or treated with 4 μM RP-6685 and/or 60nM etoposide. ( E ) Mean number of DPCs. ( F ) Mean % of DNA in the tail. ( G ) A scheme of in vivo experiments. ( H ) Mean number of GFP + FLT3(ITD); Dnmt3a KD 32Dcl3 cells (FD cells) in PBL of SCID mice untreated (Control) and treated with RP-6685, etoposide (ETO) and the combination (RP-6685+ETO). ( I ) Survival curves and MST of the mice. Error bars represent the SD; p values were calculated using one- way Anova ( A-F, H ); mice survival was evaluated by Kaplan-Meier LogRank test.
Hy13928, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hy13928/product/Selleck Chemicals
Average 93 stars, based on 1 article reviews
hy13928 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

Image Search Results


Pol θ i enhanced the sensitivity of DNMT3A deficient leukemia cells to standard drugs. ( A-D ) Sensitivity of FLT3(ITD); Dnmt3a KD 32Dcl3 cells (32D), FLT3(ITD);DNMT3A(R882H) Lin - CD34 + AML primary (AML) cells and Lin - CD34 + normal bone marrow cells (NBMCs) to Polθi (25 μM ART558, 50μM ART812, 4μM RP-6685) +/- ( A ) 2.5 nM quizartinib, ( B ) 60 nM etoposide, ( C ) 0.2 μM cytarabine, and ( D ) 0.25μM azacytidine. Results represent mean number of colonies. ( E, F ) FLT3(ITD); Dnmt3a KD 32Dcl3 cells (32D) were untreated, or treated with 4 μM RP-6685 and/or 60nM etoposide. ( E ) Mean number of DPCs. ( F ) Mean % of DNA in the tail. ( G ) A scheme of in vivo experiments. ( H ) Mean number of GFP + FLT3(ITD); Dnmt3a KD 32Dcl3 cells (FD cells) in PBL of SCID mice untreated (Control) and treated with RP-6685, etoposide (ETO) and the combination (RP-6685+ETO). ( I ) Survival curves and MST of the mice. Error bars represent the SD; p values were calculated using one- way Anova ( A-F, H ); mice survival was evaluated by Kaplan-Meier LogRank test.

Journal: bioRxiv

Article Title: DNA polymerase theta-mediated DNA repair is a functional dependency and therapeutic vulnerability in DNMT3A deficient leukemia cells

doi: 10.1101/2024.09.15.613155

Figure Lengend Snippet: Pol θ i enhanced the sensitivity of DNMT3A deficient leukemia cells to standard drugs. ( A-D ) Sensitivity of FLT3(ITD); Dnmt3a KD 32Dcl3 cells (32D), FLT3(ITD);DNMT3A(R882H) Lin - CD34 + AML primary (AML) cells and Lin - CD34 + normal bone marrow cells (NBMCs) to Polθi (25 μM ART558, 50μM ART812, 4μM RP-6685) +/- ( A ) 2.5 nM quizartinib, ( B ) 60 nM etoposide, ( C ) 0.2 μM cytarabine, and ( D ) 0.25μM azacytidine. Results represent mean number of colonies. ( E, F ) FLT3(ITD); Dnmt3a KD 32Dcl3 cells (32D) were untreated, or treated with 4 μM RP-6685 and/or 60nM etoposide. ( E ) Mean number of DPCs. ( F ) Mean % of DNA in the tail. ( G ) A scheme of in vivo experiments. ( H ) Mean number of GFP + FLT3(ITD); Dnmt3a KD 32Dcl3 cells (FD cells) in PBL of SCID mice untreated (Control) and treated with RP-6685, etoposide (ETO) and the combination (RP-6685+ETO). ( I ) Survival curves and MST of the mice. Error bars represent the SD; p values were calculated using one- way Anova ( A-F, H ); mice survival was evaluated by Kaplan-Meier LogRank test.

Article Snippet: The following DNA repair inhibitors were applied: PARPi olaparib (Selleckchem, cat# S1060), ATMi KU60019 (EMD Millipore, cat# 531978), ATRi VE-821 (Selleckchem, cat# S8007), DNA- PKi II (EMD Millipore, cat# 260961), RAD52i DI-03 , RAD51i RI-1 (Selleckchem, cat# S8077), CHK1i rabusetib: (Selleckchem, cat# S2626), CHK2i BML-277 (Selleckchem, cat# S8632), Polθi novobiocin (Selleckchem, cat# S2492), Polθi ART558 (MedChemExpress, cat# HY-141520), Polθi ART812 (MedChemExpress, cat# HY-139289), and Polθi RP-6685 (MedChemExpress, cat# HY-151462).

Techniques: In Vivo, Control